您的瑞士法律团队 – 日内瓦新办公室

9 一月 2019

Oculis SA, a clinical-stage biopharmaceutical company developing next-generation topical ophthalmic treatments in Lausanne, has entered into an agreement to in license a novel topical anti-TNF alpha antibody from Novartis. The compound, named LME 636 which will be renamed OCS-02, is based on a proprietary single-chain antibody fragment technology specifically designed for topical delivery.

The VISCHER-team advising Oculis is led by Christian Wyss (Partner) with Vincent Reardon (Senior Associate) and Vera Keller (all Corporate) and Adrian Briner (Associate) Tax.

Categories: 公司法和商法, 医疗保健, 知识产权, 房地产, 信息与通讯, 反垄断法和竞争法, 生命科学、医药、生物技术

You are currently offline. Some pages or content may fail to load.